報價延遲最少15分鐘:2025/09/05 18:01 EDT
盤後時段
|
||||
|
2.33 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.35
|
|
|
| 價值評估 |
|
盈利(現時/預測)
1.48/-2.68
|
|
企業價值
16.15M
|
| 資產負債 |
|
每股賬面淨值
-4.59
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/09/05 18:01 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease. |
